Literature DB >> 7180843

Mitochondrial NADH dehydrogenase in cystic fibrosis: enzyme kinetics in cultured fibroblasts.

B L Shapiro, L F Lam, R J Feigal.   

Abstract

Differences among cystic fibrosis (CF) genotypes (CF, obligate carriers for CF [HZ], and controls) in mitochondrial calcium pool size, oxygen (O2) consumption, and rotenone inhibition of O2 consumption led to examination of mitochondrial NADH dehydrogenase (NADH: [acceptor] oxidoreductase, E.C. 1.6.99.3). pH optima of mitochondrial NADH dehydrogenase were different in enzyme derived from whole cell homogenates of cultured skin fibroblasts of subjects with CF, HZ, and controls. We describe here apparent binding of substrate to the enzyme (Km [NADH]) in cell fractions. Km (NADH) for CF ranged from 10.9 to 16.1 micro M (no. = 7); for HZ from 20.9 to 26.3 microM (no. = 5). With three exceptions, Km for controls (no. = 12) ranged from 31.8 to 42.8 microM. Km of the three exceptional controls were 21.5, 23.7, and 22.4 microM (the latter two are identical twins). pH optima of enzyme from these three strains were no different from that of known HZ. The correlation between two kinetic parameters of an enzyme and the three CF genotypes suggests an association between the CF gene and mitochondrial NADH dehydrogenase.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7180843      PMCID: PMC1685704     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  12 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Mitrochondrial NADH dehydrogenase in cystic fibrosis.

Authors:  B L Shapiro; R J Feigal; L F Lam
Journal:  Proc Natl Acad Sci U S A       Date:  1979-06       Impact factor: 11.205

Review 3.  Research in cystic fibrosis (second of three parts).

Authors:  P A di Sant'Agnese; P B Davis
Journal:  N Engl J Med       Date:  1976-09-02       Impact factor: 91.245

4.  Preparation and properties of NADH: ubiquinone oxidoreductase (complexI), EC 1.6.5.3.

Authors:  Y Hatefi
Journal:  Methods Enzymol       Date:  1978       Impact factor: 1.600

Review 5.  A review. Cystic fibrosis at forty--quo vadis?

Authors:  P B Davis; P A di Sant'Agnese
Journal:  Pediatr Res       Date:  1980-02       Impact factor: 3.756

6.  Mitochondrial calcium uptake and oxygen consumption in cystic fibrosis.

Authors:  R J Feigal; B L Shapiro
Journal:  Nature       Date:  1979-03-15       Impact factor: 49.962

7.  Differential incorporation of 3H-thymidine into DNA in cultured skin fibroblasts derived from patients with cystic fibrosis and controls.

Authors:  L F Lam; B L Shapiro
Journal:  Life Sci       Date:  1979-06-25       Impact factor: 5.037

8.  Altered intracellular calcium in fibroblasts from patients with cystic fibrosis and heterozygotes.

Authors:  R J Feigal; B L Shapiro
Journal:  Pediatr Res       Date:  1979-06       Impact factor: 3.756

9.  Doubling time alpha-aminoisobutyrate transport and calcium exchange in cultured fibroblasts from cystic fibrosis and control subjects.

Authors:  B L Shapiro; R J Feigal; N J Laible; M H Biros; W J Warwick
Journal:  Clin Chim Acta       Date:  1978-01-02       Impact factor: 3.786

10.  Premature senescence in cultured skin fibroblasts from subjects with cystic fibrosis.

Authors:  B L Shapiro; L F Lam; L H Fast
Journal:  Science       Date:  1979-03-23       Impact factor: 47.728

View more
  8 in total

Review 1.  Cystic fibrosis-related oxidative stress and intestinal lipid disorders.

Authors:  Marie-Laure Kleme; Emile Levy
Journal:  Antioxid Redox Signal       Date:  2015-01-22       Impact factor: 8.401

2.  The renal mitochondrial dysfunction in patients with vascular calcification is prevented by sodium thiosulfate.

Authors:  Prithvika Krishnaraj; Sriram Ravindran; Gino A Kurian
Journal:  Int Urol Nephrol       Date:  2016-07-27       Impact factor: 2.370

3.  Characterization of mitochondrial function in cells with impaired cystic fibrosis transmembrane conductance regulator (CFTR) function.

Authors:  Anna Atlante; Maria Favia; Antonella Bobba; Lorenzo Guerra; Valeria Casavola; Stephan Joel Reshkin
Journal:  J Bioenerg Biomembr       Date:  2016-05-05       Impact factor: 2.945

Review 4.  CFTR activity and mitochondrial function.

Authors:  Angel Gabriel Valdivieso; Tomás A Santa-Coloma
Journal:  Redox Biol       Date:  2013-02-05       Impact factor: 11.799

5.  Disruption of interleukin-1β autocrine signaling rescues complex I activity and improves ROS levels in immortalized epithelial cells with impaired cystic fibrosis transmembrane conductance regulator (CFTR) function.

Authors:  Mariángeles Clauzure; Angel G Valdivieso; María M Massip Copiz; Gustavo Schulman; María Luz Teiber; Tomás A Santa-Coloma
Journal:  PLoS One       Date:  2014-06-05       Impact factor: 3.240

6.  The mitochondrial complex I activity is reduced in cells with impaired cystic fibrosis transmembrane conductance regulator (CFTR) function.

Authors:  Angel G Valdivieso; Mariángeles Clauzure; María C Marín; Guillermo L Taminelli; María M Massip Copiz; Francisco Sánchez; Gustavo Schulman; María L Teiber; Tomás A Santa-Coloma
Journal:  PLoS One       Date:  2012-11-21       Impact factor: 3.240

Review 7.  Circulating biomarkers of antioxidant status and oxidative stress in people with cystic fibrosis: A systematic review and meta-analysis.

Authors:  Adam J Causer; Janis K Shute; Michael H Cummings; Anthony I Shepherd; Mathieu Gruet; Joseph T Costello; Stephen Bailey; Martin Lindley; Clare Pearson; Gary Connett; Mark I Allenby; Mary P Carroll; Thomas Daniels; Zoe L Saynor
Journal:  Redox Biol       Date:  2020-01-23       Impact factor: 11.799

8.  Early pathogenesis of cystic fibrosis gallbladder disease in a porcine model.

Authors:  Keyan Zarei; Mallory R Stroik; Nick D Gansemer; Andrew L Thurman; Lynda S Ostedgaard; Sarah E Ernst; Ian M Thornell; Linda S Powers; Alejandro A Pezzulo; David K Meyerholz; David A Stoltz
Journal:  Lab Invest       Date:  2020-07-27       Impact factor: 5.502

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.